Search Within

Michael Morris

Formats
  1. Meeting Abstract (276)
  2. Journal Article (268)
  3. Review (21)
  4. Book Section (6)
  5. Editorial (6)
  6. Correspondence (4)
  7. Guidelines (3)
  8. Miscellaneous (2)
  9. Conference Paper (1)
  10. Research Letter (1)
Groups
  1. Department of Medicine (588)
  2. Genitourinary Oncology Service (588)
  3. Solid Tumor Oncology Division (588)
  4. Radiology, Department of (165)
  5. GSK Faculty (161)
  6. Molecular Imaging and Therapy Service (142)

More Groups

People
  1. Howard Scher (217)
  2. Steven Larson (93)
  3. Susan Slovin (90)
  4. Dana Rathkopf (79)
  5. Daniel Danila (54)
  6. Glenn Heller (54)

More People

Years
  1. 2025 (29)
  2. 2024 (50)
  3. 2023 (40)
  4. 2022 (50)
  5. 2021 (42)
  6. 2020 (35)

More Years

Publications
  1. Journal of Clinical Oncology (240)
  2. Journal of Nuclear Medicine (45)
  3. Clinical Cancer Research (33)
  4. Annals of Oncology (30)
  5. Cancer (18)
  6. European Urology (18)

More Publications

Publishers
  1. American Society of Clinical Oncology (250)
  2. Society of Nuclear Medicine (45)
  3. American Association for Cancer Research (43)
  4. Oxford University Press (41)
  5. Elsevier Science, Inc. (40)
  6. Elsevier Inc. (27)

More Publishers

Results (588)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical versus radiographic progression and overall survival for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) from COU-AA-302
    Meeting Abstract

    Ryan, C. J.; Kheoh, T.; Scher, H. I.; De Porre, P.; Yu, M. K.; Morris, M. J.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1 169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Morris, M. J.; Vogelzang, N.; Sartor, O.; Armour, A.; Groaning, M.; Robarts, A.; Petrylak, D. P.; Tolcher, A. W.; Gordon, M. S.; Babiker, H. M.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase II trial of abiraterone acetate (AA) without prednisone in castration resistant prostate cancer (CRPC)
    Meeting Abstract

    McKay, R. R.; Werner, L.; Jones, A.; Choudhury, A. D.; Pomerantz, M.; Sweeney, C.; Bubley, G. J.; Slovin, S. F.; Morris, M. J.; Kantoff, P. W.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance)
    Meeting Abstract

    George, D. J.; Halabi, S.; Starr, M. D.; Hurwitz, H.; Brady, J. C.; Barak, I.; Morris, M. J.; Rini, B. I.; Small, E. J.; Kim, W.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase 3 prognostic analysis of the automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Armstrong, A. J.; Edenbrandt, L.; Bondesson, E.; Anand, A.; Nordle, O.; Carducci, M. A.; Morris, M. J.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Translating prostate cancer working group (PCWG) criteria into a quantitative progression biomarker in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Anand, A.; Heller, G.; Scher, H. I.; Morris, M. J.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Observational longitudinal study of pain in men with metastatic castrate-resistant prostate cancer: Aim 1. Rates of pain palliation and pain progression as indicated by self-reported daily pain and analgesic use
    Meeting Abstract

    Bennett, A. V.; Shouery, M.; Wang, M.; Whang, Y. E.; Milowsky, M.; Drier, S.; Carr, P.; Graff, J. N.; Morris, M. J.; Scher, H. I.; more...
    Quality of Life Research (2017)

    Fulltext@MSK | Save
  • Effective prostate-specific membrane antigen-based (18)F-DCFPyL-guided cryoablation of a single positive site in a patient believed to be more metastatic on (11)C-choline PET/CT
    Journal Article

    Cornelis, F. H.; Durack, J. C.; Morris, M. J.; Scher, H. I.; Solomon, S. B.
    Clinical Nuclear Medicine (2017)

    Fulltext@MSK | Save
  • Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy
    Journal Article

    Beltran, H.; Wyatt, A. W.; Chedgy, E. C.; Donoghue, A.; Annala, M.; Warner, E. W.; Beja, K.; Sigouros, M.; Mo, F.; Fazli, L.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Morris, M.; Vogelzang, N. J.; Sartor, O.; Armour, A.; Groaning, M.; Messmann, R.; Robarts, A.; Petrylak, D. P.; Tolcher, A.; Gordon, M. S.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save